Probing benzenesulfonamide-thiazolidinone hybrids as multitarget directed ligands for efficient control of type 2 diabetes mellitus through targeting the enzymes: α-glucosidase and carbonic anhydrase II

Eur J Med Chem. 2024 May 5:271:116434. doi: 10.1016/j.ejmech.2024.116434. Epub 2024 Apr 20.

Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by improper expression/function of a number of key enzymes that can be regarded as targets for anti-diabetic drug design. Herein, we report the design, synthesis, and biological assessment of two series of thiazolidinone-based sulfonamides 4a-l and 5a-c as multitarget directed ligands (MTDLs) with potential anti-diabetic activity through targeting the enzymes: α-glucosidase and human carbonic anhydrase (hCA) II. The synthesized sulfonamides were evaluated for their inhibitory activity against α-glucosidase where most of the compounds showed good to potent activities. Compounds 4d and 4e showed potent inhibitory activities (IC50 = 0.440 and 0.3456 μM), comparable with that of the positive control (acarbose; IC50 = 0.420 μM). All the synthesized derivatives were also tested for their inhibitory activities against hCA I, II, IX, and XII. They exhibited different levels of inhibition against these isoforms. Compound 4d outstood as the most potent one against hCA II with Ki equals to 7.0 nM, more potent than the reference standard (acetazolamide; Ki = 12.0 nM). In silico studies for the most active compounds within the active sites of α-glucosidase and hCA II revealed good binding modes that can explain their biological activities. MM-GBSA refinements and molecular dynamic simulations were performed on the top-ranking docking pose of the most potent compound 4d to confirm the formation of stable complex with both targets. Compound 4d was screened for its in vivo antihyperglycemic efficacy by using the oral glucose tolerance test. Compound 4d decreased blood glucose level to 217 mg/dl, better than the standard acarbose (234 mg/dl). Hence, this revealed its synergistic mode of action on post prandial hyperglycemia and hepatic gluconeogenesis. Thus, these benzenesulfonamide thiazolidinone hybrids could be considered as promising multi-target candidates for the treatment of type II diabetes mellitus.

Keywords: Benzenesulfonamide; Carbonic anhydrase; Thiazolidinone; Type II diabetes mellitus; α-glucosidase.

MeSH terms

  • Animals
  • Benzenesulfonamides*
  • Carbonic Anhydrase II* / antagonists & inhibitors
  • Carbonic Anhydrase II* / metabolism
  • Carbonic Anhydrase Inhibitors* / chemical synthesis
  • Carbonic Anhydrase Inhibitors* / chemistry
  • Carbonic Anhydrase Inhibitors* / pharmacology
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Type 2* / drug therapy
  • Dose-Response Relationship, Drug
  • Glycoside Hydrolase Inhibitors* / chemical synthesis
  • Glycoside Hydrolase Inhibitors* / chemistry
  • Glycoside Hydrolase Inhibitors* / pharmacology
  • Humans
  • Hypoglycemic Agents* / chemical synthesis
  • Hypoglycemic Agents* / chemistry
  • Hypoglycemic Agents* / pharmacology
  • Ligands
  • Male
  • Molecular Docking Simulation
  • Molecular Structure
  • Rats
  • Rats, Wistar
  • Structure-Activity Relationship
  • Sulfonamides* / chemical synthesis
  • Sulfonamides* / chemistry
  • Sulfonamides* / pharmacology
  • Thiazolidines* / chemical synthesis
  • Thiazolidines* / chemistry
  • Thiazolidines* / pharmacology
  • alpha-Glucosidases* / metabolism

Substances

  • Carbonic Anhydrase II
  • alpha-Glucosidases
  • Benzenesulfonamides
  • Sulfonamides
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Carbonic Anhydrase Inhibitors
  • Ligands
  • Thiazolidines